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OBJECTIVES: Ticagrelor, co-administered with acetylsalicylic acid, is a new anti-
platelet therapy for patients with acute coronary syndrome (ACS) aimed at pre-
venting thrombotic events [i.e., cardiovascular mortality, myocardial infarction
(MI) and stroke]. The goal was to determine the cost per life year gained (LYG) for
ticagrelor compared to current standard therapy (clopidogrel) using a cost-effec-
tiveness analysis framework based on the published results from the Platelet In-
hibition and Patient Outcomes (PLATO). METHODS: A Markov model framework
was developed in order to evaluate the costs and benefits of ticagrelor over a life-
time time horizon. The clinical outcomes consisted of four health states: “MI”,
“Stroke”, “All Cause Mortality” and “Recovered”, with frequencies derived from the
pivotal PLATO study at one year. These health states were extrapolated into the
future via “Live” and “Die” scenarios. Resources and costs (2010 Canadian $) were
obtained from the literature or public domain. A 5% discount rate was applied to all
the cost and clinical inputs after the first year. RESULTS: An incremental cost
effectiveness ratio (ICER) of $1125/LYG was determined. Probabilistic sensitivity
analysis presented greater than 99% of all iterations resulting in an ICER less than
$50,000/LYG. The economic model was most sensitive to the probability of death
within one year of ticagrelor or clopidogrel treatment. CONCLUSIONS: Based on
outcomes in the PLATO trial, the use of ticagrelor instead of clopidogrel for treat-
ment of ACS in Canada is associated with an ICER of $1,125/LYG.
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OBJECTIVES: Diabetic nephropathy significantly increases the risk of cardiovascu-
lar disease (CVD) and end-stage renal disease (ESRD) in hypertensive patients.
According to the AVOID study, the direct renin-inhibitor aliskiren, when added to
losartan and optimal antihypertensive therapy in patients with hypertension, type
2 diabetes (T2DM) and diabetic nephropathy, significantly (p0.001) reduced albu-
minuria by 20% over 6 months, as assessed by urinary albumin-creatinine ratio
(UACR). This simulation examines the potential long-term clinical benefits and
costs of add-on therapy with aliskiren in hypertensive patients with T2DM and
diabetic nephropathy in Germany. METHODS: We developed a micro-simulation
model to depict the progression to ESRD, measured by UACR levels over time.
Patients at model entry were on maximal recommended doses of losartan and
optimal antihypertensive therapy, and either continued this regimen or received
aliskiren as an add-on therapy. In scenario analyses, different assumptions on the
maintenance of the 20% UACR-reduction were made. Expected costs of pharmaco-
therapy and medical care were calculated based on German-specific sources over
10 years applying an annual discount rate of five percent. Sensitivity analyses were
conducted to analyze the impact of different input parameters. RESULTS: Add-on
therapy with aliskiren was projected to reduce the risk of ESRD by 1.8% and delay
the onset of ESRD by 0.15 years assuming that the effects of aliskiren on UACR-
reduction are maintained over 5 years. While discounted costs of pharmacother-
apy were estimated to increase by 1762€ per patient with aliskiren, costs of ESRD-
related care were estimated to decrease by 3804€ over this same period, yielding
total cost savings. Findings were sensitive to the duration over which the benefits
of add-on therapy with aliskiren were assumed to be maintained. CONCLUSIONS:
In hypertensive patients with T2DM and diabetic nephropathy receiving losartan
and optimal antihypertensive therapy, add-on therapy with aliskiren is projected
to yield clinical benefits and cost savings.
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OBJECTIVES: To evaluate the cost-effectiveness of a one-year treatment period
with 90 mg twice daily Ticagrelor compared to 75 mg/day Clopidogrel in acute
coronary syndrome (ACS) patients with or without ST-segment elevation from the
third-party-payer perspective in Greece. METHODS: An existing model consisting
of a one-year decision tree based on the PLATO trial data and a long-term extrap-
olation Markov model was adapted to the Greek health-care setting. Utility values
obtained from the PLATO trial were used to estimate quality-adjusted life years
(QALY) for both the decision tree and the Markov model. Local unit costs in com-
bination with resource use data collected within the PLATO trial were used to
estimate the costs incorporated in the analysis. These costs included treatment
and medication costs, cost for the management of adverse events, hospitalization,
outpatient visits, rehabilitation and nursing costs. Cost-effectiveness and cost-
utility was expressed as the incremental cost per life year gained (LYG) and QALY
gained (ICER), respectively. RESULTS: Implementing a lifetime horizon, the analy-
sis predicts a discounted survival of 11.63 years in the Ticagrelor treatment group
and 11.48 years in the Clopidogrel treatment group. The corresponding discounted
QALYs were 9.78 and 9.65, respectively. The cumulative lifetime costs per patient
were €24,967 and €24,170, for Ticagrelor and Clopidogrel treatment arm, respec-
tively. The ICER was €5239 for each LYG and €6079 for each QALY saved. Imple-
menting a 5-year horizon analysis, results in a discounted survival of 4.36 and 4.31
years for Ticagrelor and Clopidogrel treatment respectively. The QALYs and costs
per patient were 3.77 and €15,239 for Ticagrelor and 3.73 and €14,604 for Clopi-
dogrel. The ICER in this case was €12,631 for each LYG and €14,176 for each QALY
saved. CONCLUSIONS:One-year treatment with Ticagrelor in addition to aspirin is
a cost-effective treatment option vs Clopidogrel plus aspirin in patients with ACS in
Greece.
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OBJECTIVES: Chronic heart failure (HF) is a major cause of morbidity and mortality
and a growing burden to the healthcare system. The objective was to assess the
cost-effectiveness of candesartan cilexetil, an angiotensin II type 1 receptor blocker
(ARB) for the treatment of HF in the Austrian setting. METHODS: A pre-specified
economic evaluation was conducted on resource utilization prospectively col-
lected alongside the CHARM programme. We examined the effect of adding can-
desartan in all 7599 patients randomized. All patients were considered to have
been managed in Austria. Our analysis takes the perspective of a third party payer.
CHARM consisted of a series of parallel randomized clinical trials comparing can-
desartan with placebo (standard therapy) in patients with NYHA Class II-IV HF: -
CHARM-Alternative (LVEF 40% patients not receiving ACE inhibitors because of
previous intolerance); - CHARM-Added (LVEF 40% patients currently receiving
ACE inhibitors); - or CHARM-Preserved (LVEF  40% patients). Primary outcome of
the overall programme: all-cause mortality; for the component trials: composite of
cardiovascular death and hospital admission for HF. Resource use was collected
prospectively on drug treatment, patients admitted to hospital, admissions for
cardiovascular reasons, and procedures/operations. These data were used to de-
termine the additional direct costs incurred, and potential savings made with can-
desartan. Unit costs were elicited from published Austrian sources in accordance
with local guidelines. 2008 was chosen as the price year. RESULTS: Adjunctive
treatment with candesartan in CHARMAlternative and CHARM-Added led to clin-
ical benefits and, depending on the trial, to either cost savings or low additional
costs. CONCLUSIONS: Not only does candesartan improve all important clinical
outcomes in HF but also offers these benefits at little or no additional cost to the
health care system; indeed, its use in patients with HF and reduced LV systolic
function may lead to an actual reduction in the direct costs of healthcare in Austria.
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OBJECTIVES: Increasing real-life adherence to statin therapy is important to
achieve the clinical benefits of reducing cardiovascular events (CVEs) reported in
randomized clinical trials (RCTs). The aim of this pilot study was to determine the
cost-effectiveness of a pharmaceutical care intervention program in community
pharmacies, aimed to increase statin adherence for the secondary prevention of
CVEs. METHODS: Meta-analyses of five RCTs were performed to determine the
clinical efficacy of statins for secondary prevention, adjusted for different levels of
therapy adherence. A Markov model with a lifelong time horizon was developed to
estimate the influence of statin adherence on CVEs: stroke, myocardial infarction
(MI), revascularization and mortality. Baseline adherence was calculated in a large
Dutch prescription database, using the proportion of days covered (PDC) method.
The effect of pharmacists’ interventions on statin adherence was derived from
literature. A Dutch health care provider’s perspective was adopted; costs and ef-
fects were discounted at 4.0% and 1.5% per annum, respectively. RESULTS: Adher-
ence to statin therapy for secondary prevention in The Netherlands was 73.0%. In
a cohort of 1000 patients, a 7% increase in adherence resulted in a reduction of 1.9
non-fatal strokes, 0.5 fatal strokes, 7.9 non-fatal MIs, 3.7 fatal MIs and 9.1 revascu-
larizations. Additional medication and intervention costs in the intervention group
were €56,000; the cost-savings due to reduced CVEs were €109,000. Overall, the
pharmaceutical care program resulted in 53 quality-adjusted life years (QALYs)
gained and cost-savings of €53,000. CONCLUSIONS: Pharmaceutical care programs
in community pharmacies can improve statin adherence for secondary prevention
of CVEs. At a reasonable level of intervention effectiveness, the programs resulted
in both clinical benefits and cost-savings. The model developed in this pilot study
will be used to estimate the cost-effectiveness of a pharmaceutical care program
(the MeMO intervention) in the The Netherlands that is currently under clinical
evaluation.
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OBJECTIVES: The multicentre, double-blind, randomized PLATO trial showed that
treatment with ticagrelor  aspirin reduced the risk of myocardial infarction,
stroke or death from vascular causes without a significant increase in major bleed-
ing compared to clopidogrel  aspirin treatment in patients with ACS. The long-
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